Name: | Insulin Lispro |
---|---|
Name (isomeric): | DB00046 |
Drug Type: | biotech |
Description: | Insulin that has been modified so that the B-chain contains a LYSINE at position 28 instead of a PROLINE and a PROLINE at position 29 instead of a LYSINE. |
Brand: | Humalog, Humalog Mix 75/25 Pen |
Brand name mixture: | Humalog Mix25(insulin lispro (25 units/ml) + insulin lispro protamine (75 units/ml)), Humalog Mix50/50(insulin lispro (50 units/ml) + insulin lispro protamine (50 units/ml)), Humalog Mix50(insulin lispro (50 units/ml) + insulin lispro protamine (50 units/ml)), Humalog Mix75/25(insulin lispro (25 units/ml) + insulin lispro protamine (75 units/ml)) |
Category: | Hypoglycemic Agents, Antidiabetic |
CAS number: | 133107-64-9 |
Indication: | For the treatment of Type 1 or 2 diabetes mellitus. To be used in conjunction with an intermediate or long-acting insulin except when used in a continuous insulin infusion pump. |
---|---|
Pharmacology: |
Insulin is a natural hormone produced by beta cells of the pancreas. In non-diabetic individuals, a basal level of insulin is supplemented with insulin spikes following meals. Increased insulin secretion following meals is responsible for the metabolic changes that occur as the body transitions from a postabsorptive to absorptive state. Insulin pro...
show more » |
Mechanism of Action: |
Insulin lispro binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates ...
show more » |
Absorption: | Rapidly absorbed following subcutaneous administration. To be administer within 15 minutes before a meal. |
Biotransformation: | Insulin is predominantly cleared by metabolic degradation via a receptor-mediated process. |
Half Life: | 1 hour |
Toxicity: | Inappropriately high dosages relative to food intake and/or energy expenditure may result in severe and sometimes prolonged and life-threatening hypoglycemia. Neurogenic (autonomic) signs and symptoms of hypoglycemia include trembling, palpitations, sweating, anxiety, hunger, nausea and tingling. Neuroglycopenic signs and symptoms of hypoglycemia include difficulty concentrating, lethargy/weakness, confusion, drowsiness, vision changes, difficulty speaking, headache, and dizziness. Mild hypoglycemia is characterized by the presence of autonomic symptoms. Moderate hypoglycemia is characterized by the presence of autonomic and neuroglycopenic symptoms. Individuals may become unconscious in severe cases of hypoglycemia. Rare cases of lipoatrophy or lipohypertrophy reactions have been observed. |
Affected organisms: | Humans and other mammals |
Food interaction: |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Drug interaction: |
|